Promising results for Poolbeg Pharma’s POLB 001

Poolbeg Pharma has announced promising pre-clinical results for POLB 001, a novel therapeutic aimed at mitigating cytokine release syndrome (CRS) associated with cancer immunotherapies. Presented at the 66th American Society of Hematology Annual Meeting, the study indicates that POLB 001 significantly reduces CRS symptoms, potentially transforming treatments for hematological malignancies. Poolbeg’s consultant Clinical Advisor, Mark Sumeray, said the  “data presented at ASH are promising, demonstrating statistically significant cytokine inhibition and a dose dependent reduction in clinical CRS.”

POLB 001 has demonstrated its efficacy in humanized tumor-bearing mouse models, showing superior performance compared to Adalimumab, the current gold standard anti-TNF antibody. Administered twice daily over a five-day period, POLB 001 not only reduced clinical CRS scores but also decreased peak serum levels of inflammatory cytokines such as TNF, IL-4, IL-6, IL-8, and MIP-1α, showcasing its potential as a prophylactic treatment. Given the high unmet medical need in this area, these findings underscore POLB 001’s potential to enhance the safety profile of cancer immunotherapies and extend their reach to more patients, thereby having a significant impact on the hematological treatment landscape.

Poolbeg Pharma’s recent pre-clinical success with POLB 001 represents a significant advancement in addressing cancer immunotherapy-induced CRS. As the company gears up for Phase 2 clinical trials, POLB 001 stands as a promising candidate to improve patient outcomes and enhance the safety of cancer therapies, highlighting Poolbeg’s commitment to innovative solutions in high-need areas.

Contact Marcus for more details.